Breast Cancer Research and Treatment

, Volume 137, Issue 2, pp 465–470

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

  • Holm Eggemann
  • Atanas Ignatov
  • Bobbie J. Smith
  • Udo Altmann
  • Gunter von Minckwitz
  • Freidrich W. Röhl
  • Mark Jahn
  • Serban-Dan Costa
Clinical trial

Abstract

To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2–115) months. Median age at diagnosis was 68 (range 36–91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient’s age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13–2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.

Keywords

Male breast cancer Tamoxifen Aromatase inhibitor Adjuvant treatment 

List of abbreviations

AI

Aromatase inhibitors

CI

Confidence interval

DCIS

Ductal carcinoma in situ

ER

Estrogen receptor human epidermal growth factor

HER2

Receptor 2

HR

Hazard ratio

MBC

Male breast cancer

N

Number

OS

Overall survival

PR

Progesterone receptor

TAM

Tamoxifen

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Holm Eggemann
    • 1
  • Atanas Ignatov
    • 1
  • Bobbie J. Smith
    • 2
  • Udo Altmann
    • 3
  • Gunter von Minckwitz
    • 4
  • Freidrich W. Röhl
    • 5
  • Mark Jahn
    • 6
  • Serban-Dan Costa
    • 1
  1. 1.University Women’s ClinicOtto-von-Guericke UniversityMagdeburgGermany
  2. 2.Hannover Medical SchoolHannoverGermany
  3. 3.Clinical Tumor Registry CoordinationJustus Liebig UniversityGiessenGermany
  4. 4.German Breast GroupNeu-IsenburgGermany
  5. 5.Institute of Biometrics and Medical InformaticsOtto-von-Guericke UniversityMagdeburgGermany
  6. 6.Helios Klinikum, Berlin BuchBerlinGermany

Personalised recommendations